Yet something had changed.
For months, she had lived under the weight of a story written about her by people who wanted her discredited.
Now that story was being questioned.
And she had evidence that her professional life might not be over.
The next several days passed with unnerving speed.
The independent committee contacted the external monitoring provider that had supplied temperature sensors to Northline's warehouses.
The company operated a digital platform that stored raw temperature readings and system-event histories.
Its records were distinct from the summary reports prepared by Northline management.
The provider confirmed that archived data existed for the relevant period.
The records had not been routinely available to the transaction team because the acquisition review had relied on exported reports prepared by the warehouse operator.
That distinction was important.
An exported report could legitimately include annotations or adjustments.
But the independent monitoring system retained underlying readings and event histories that could be compared against the explanations entered later.
The committee authorized a controlled review.
Specialists obtained the records through appropriate company and provider channels.
They checked timestamps, device identifiers, calibration histories, and maintenance references.
At first, the differences seemed technical.
Several reports contained intervals marked as sensor faults.
The underlying system showed corresponding temperature deviations.
Some deviations were brief.
Others lasted much longer.
The forensic accountants compared the raw data with the corrective-action documentation.
They found repeated instances where the supporting reports did not establish that products had remained within required storage conditions.
There were also inconsistencies in when certain corrective-action classifications had been entered.
In some cases, the approval appeared days after the original event.
In others, the system history showed that a report had been changed after questions arose during the acquisition review.
The findings did not prove that every affected product was unsafe.
Product stability depended on the specific medicine, the duration and extent of any excursion, and qualified quality-assurance evaluation.
But the findings raised serious questions about whether the relevant decisions had been properly documented before products were released.
The committee expanded its review.
It requested original records from additional warehouses.
It asked for communication logs concerning the technical annex.
It sought to identify who had authorized the disputed certification.
And it contacted relevant regulatory advisers to determine whether any product holds, notifications, or further safety assessments were required.